Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma, Inc. reported encouraging preliminary data from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer and robust activity of NXP900 in non-small cell cancer cell lines. Several clinical data updates are expected in the second half of 2024. The company remains cash flow efficient with approximately $19.5 million in cash, providing runway into the second half of 2025. Financially, cash and cash equivalents increased to $19.5 million from $19.1 million, with a net loss of $4.2 million for the first quarter of 2024, including $1.3 million in non-cash stock-based compensation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.